- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/102 - PasteurellaHaemophilus
Détention brevets de la classe A61K 39/102
Brevets de cette classe: 373
Historique des publications depuis 10 ans
|
33
|
28
|
27
|
23
|
21
|
23
|
17
|
10
|
14
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1625 |
44 |
| Intervet Inc. | 907 |
17 |
| Intervet International B.V. | 1302 |
14 |
| Research Institute at Nationwide Children's Hospital | 598 |
9 |
| The United States of America, as represented by the Secretary of Agriculture | 1130 |
8 |
| Boehringer Ingelheim Animal Health USA Inc. | 420 |
8 |
| Engineered Antigens Inc. | 12 |
7 |
| Hunter Immunology Limited | 8 |
6 |
| Nationwide Children's Hospital, Inc. | 86 |
6 |
| Sanofi Pasteur SA | 78 |
6 |
| Serum Institute of India Private Limited | 108 |
6 |
| Biotechnology Research and Development Corporation | 13 |
5 |
| Merial, Inc. | 216 |
5 |
| Cansino Biologics Inc. | 81 |
5 |
| Vaxxinova US, Inc. | 44 |
5 |
| Novartis AG | 10481 |
4 |
| Boehringer Ingelheim Vetmedica, Inc. | 107 |
4 |
| Janssen Pharmaceuticals, Inc. | 440 |
4 |
| Longhorn Vaccines and Diagnostics, LLC | 88 |
4 |
| Qu Biologics Inc. | 27 |
4 |
| Autres propriétaires | 202 |